
About this episode
The deepening understanding of the biology of aging is giving rise to a growing list of companies that seek not only to address diseases of aging, but find ways to extend the healthy years of life. LongeVC is a venture capital firm focused on seed and early-stage investment in longevity statups. It’s also built a community of like-minded companies to support startups, as well as an acceleration program for them. We spoke to Sergey Jakimov, founding partner of LongeVC, about the firm’s approach to investing, what constitutes a longevity play for it, and the network of companies it has assembled to help advance the startups it backs.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending